Biomarkers Consortium

FNIH Biomarkers Consortium

Spotlight

BC Nature Discovery

The Clinical Pharmacology & Therapeutics publication describes how the Biomarkers Consortium works, highlights its accomplishments and explains its strategic expansion.

Q&A with George H. Talbot

FNIH Biomarkers Consortium and Critical Path Institute achieve the first ever qualification of a clinical safety biomarker by the U.S. Food and Drug Administration.

Lawrence Schwartz

In this Q&A, George H. Talbot, M.D., HABP/VABP Project Principal Investigator and Project Team Co-Chair, discusses the project’s history and significant achievements to-date that will help design more efficient clinical trials and facilitate the antibiotic approval process.

Vision

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventative medicine and medical diagnostics.

Mission

The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient's illness or lifespan. Its goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines and therapies for prevention, early detection, diagnosis and treatment of disease.

 

Front Page: